Prevent rising uric acid levels

In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia

THE POWER TO PREVENT RISING URIC
ACID LEVELS
IS IN YOUR HANDS

Explore Clinical Data

Prevent rising uric acid levels

In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia

THE POWER TO PREVENT RISING URIC
ACID LEVELS
IS IN YOUR HANDS

Explore Clinical Data

In a phase 3 trial, ELITEK given prophylactically (prior to anticancer therapy) maintained normal uric acid levels (≤7.5 mg/dL) in significantly more patients (87%, n=92) vs allopurinol (66%, n=91) between 3 and 7 days after initiation of antihyperuricemic treatment (P=0.001) (primary endpoint).1

Mechanism of action

MOA

mechanism of action

See how ELITEK functions differently than allopurinol

EXPLORE ELITEK MOA

Identify patients at risk

IDENTIFY

patients at risk

Find out what your peers are saying about patients at higher risk for TLS

SEE TLS RISK FACTORS

Request a rep

REQUEST

a rep

Get in contact with an ELITEK representative

CONTACT A REP

Mechanism of action

MOA

mechanism of action

See how ELITEK functions differently than allopurinol

EXPLORE ELITEK MOA
Identify patients at risk

IDENTIFY

patients at risk

Find out what your peers are saying about patients at higher risk for TLS

SEE TLS RISK FACTORS
Request a rep

REQUEST

a rep

Get in contact with an ELITEK representative

CONTACT A REP
CareASSIST® Patient Support by Sanofi Genzyme. CareASSIST offers access support for eligible patients prescribed ELITEK
CareASSIST® ELITEK® (rasburicase)
CareASSIST® Patient Support by Sanofi Genzyme. CareASSIST offers access support for eligible patients prescribed ELITEK
CareASSIST® ELITEK® (rasburicase)

CAREASSIST PROGRAM

Find resources and support for eligible patients

Access and support

access and reimbursement

Assistance navigating the insurance process, including benefits investigations, claims assistance, and information about prior authorizations and appeals.

Financial assistance

financial assistance

CareASSIST offers programs and services that can help eligible patients with the cost of ELITEK.

Resource support

resource support

Information on independent support services for patients and caregivers, as well as product ordering and replacement information.

Reference: 1. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213.